Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 24,900 shares, an increase of 236.5% from the June 30th total of 7,400 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average trading volume of 25,800 shares, the short-interest ratio is currently 1.0 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on shares of Akari Therapeutics in a research note on Sunday. They issued a “sell” rating for the company.
View Our Latest Stock Report on AKTX
Akari Therapeutics Stock Down 0.5 %
Institutional Investors Weigh In On Akari Therapeutics
An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX – Free Report) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.06% of the company’s stock.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Featured Stories
- Five stocks we like better than Akari Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Beauty Retailer Stock Brings Early Christmas for Value Investors
- Investing in large cap stocks: Diving into big caps
- Ford Stock EPS Disappoints, Shares Plummet After-Hours
- How to Most Effectively Use the MarketBeat Earnings Screener
- How Much Should You Be Investing? Try Our Calculators
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.